ARGRX™ is the only Patented Edible Computer Chip® that delivers a specific dose of an Arginine molecule to a targeted delivery site in the human body.

The benefits of any L-Arginine product or formula is based on its ability to deliver L-Arginine to site-specific-destinations in the human body, such as:

The production of Nitric Oxide in elevating serum levels of Arginine
L-Arginine crossing the Blood-Brain-Barrier (BBB)
Stimulation of muscle mitochondria

Essential to any effective L-Arginine formula, is the ability to deliver elemental Arginine to targeted sites in the body, utilizing Threshold Plateau doses.

L-Arginine benefits are dose and timing-dependent, and reach a Threshold Plateau at specific elemental doses.

ARGRX™ is the only L-Arginine product on the market that has undergone 25-years of research to determine Arginine human dosing guidelines. These specific dosing-guidelines are incorporated into every ARGRX™ product.


Patented Pharmaceutical-Grade L-Arginine
State-of-the-Art L-Arginine Formulas
The only proven Safe L-Arginine (25 years)
L-Arginine bound to Blind Amino Acid® Riders
Patented L-Arginine for Clinical Trials
Patented L-Arginine Formulas for the Nutraceutical Industry
Patented Nitric Oxide Formulas
Private Label L-Arginine formulas
L-Arginine for Genetic Polymorphisms
The only Certified Low Glycemic L-Arginine




Effective doses of L-Arginine range from 5,000 mg (5 grams) to 20,000 mg (20 g). Said doses must be ingested at one time.

Time-released L-Arginine is not effective, as dosages must be delivered and metabolized in 5-20 gram increments.

L-Arginine must be administered in humans in elemental form. Elemental refers to the net dose of an element, and not the gross weight. Example: Many forms of L-Arginine contain 60 to 80 % pure L-Arginine, and the rest is inert filler. If an L-Arginine product label represents the gross weight and not the net weight, the actual amount of L-Arginine is not represented or known to the consumer.

If the net dose of deliverable L-Arginine is less than 5 grams of elemental L-Arginine, the product cannot be considered to be an efficacious L-Arginine formula.

In calculating doses in L-Arginine products, there are 1000 mg in a gram (g).





ARGRX™ is the first L-Arginine complex to contain Embedded Tracer Technology (ETT). This allows tracking of authentic ARGRX™ products and formulas.

As an Edible Computer Chip®, ARGRX™ is used as the base of many different Arginine formulas and products. A Licensing Agreement is required for any use of ARGRX™ in a product.

Any formula or product that contains ARGRX™ is required to display the Official ARGRX™ logo on products and attendant marketing literature.






NITRIC OXIDE

Nitric Oxide (NO) is widely recognized as a key signaling molecule in human health and is associated with a variety of tissues and organs that affect cardiovascular disease, inflammatory disease and male erectile dysfunction.

ARGRX™ research and patents focus on genetically-targeted solutions for optimal health in humans, including L-Arginine Nitric Oxide delivery systems. The unique and patented ARGRX™ Nitric Oxide (NO) transport systems provide a specific signaling cell matrix designed to achieve appropriate cellular goals and provide health benefits of NO.

Two of the Nitric Oxide (NO) patents and formulas, called NO FOR HEALTH, are exclusively licensed to Boresha International, and represents one of several technologies that ARGRX™ researchers developing for delivering NO to target tissues for therapeutic benefit.





Since its discovery as a signaling molecule 10 years ago, Nitric Oxide (NO) has been demonstrated to be ubiquitous and essential to a broad range of biological functions, but potentially dangerous in human use (Johns Hopkins/JAMA).

ARGRX™ is the only long-term proven safe delivery system for the amino acid L-Arginine. The patents encompass the only Nitric Oxide (NO) formulas that contain Blind Amino Acid® Riders, which render NO and L-Arginine safe for human use long-term.




The rate of (Nitric Oxide) NO production is critically dependent on the bioavailability of Arginine. NO is a highly reactive, short-lived, lipophilic molecule with a half life of a few seconds. L-Arginine Nitric Oxide (NO) formulas are capable of producing excessive NO or reduced endogenous NO production.

Reduced arginine availability results in reduced NO synthesis. Arginine availability for NO synthesis is regulated by de novo arginine synthesis, arginase activity, and cellular arginine transport. Arginase is generated by excessive NO levels, and is to be avoided under any circumstance in an L-Arginine or NO formula.

Excess (excessive) NO creates a toxic environment in the human body, and low levels of NO (reduced endogenous NO) are ineffective, so NO highs and lows are to be avoided. In terms of fertility in males, NO reduces or inhibits sperm motility, while NOS inhibitors, which inhibit the formation of NO, prevent the reduction of sperm motility, indicating a role for the L-arginine-NO pathway in the modulation of sperm motility and motility survival.

Sperm motility is negatively affective by both reduced and excessive endogenous Nitric Oxide (NO). The mechanism of reduced fertility in males, related to NO, is a function of the effect of reactive oxygen species (ROS) on sperm membranes, which depresses sperm function. Stress also exacerbates reduced motility of sperm. Excessive NO levels in seminal plasma are associated with poor sperm quality.

Excessive generation of NO can be toxic and reduce sperm motility. Further, excessive NO contributes to the formation of a highly toxic anion of peroxidation, called peroxynitrite. The unpaired electrons of NO and O2 define peroxynitrite as a 1-or-2-electron oxidant and nitrating agent, and not a typical free radical.

Numerous clinical studies have demonstrated that peroxidation decreases sperm count and motility, and loss of the capacity of the spermatozoon to undergo the acrosome reaction and fertilization.

Therefore, NO formulas and products must be produced under strict GMP manufacturing guidelines utilizing long-term proven methodologies in L-arginine biochemistry.

The manufacture of NO formulas and products should not be attempted by persons unfamiliar with L-Arginine NO toxic byproducts and the Blind Amino Acid personality of amino acids, such as Arginine.




 
Backed by United States Patent, Trademarks, and Copyrights.

No part of this website may be copied and placed on another website, or used for any purpose whatsoever.


These statements have not been evaluated by the Food & Drug Administration. The products promoted herein are not intended to diagnose, treat, cure, or prevent any disease.


 
Copyright © 2008-2009 ArgRX